Medicinal Chemistry of New Compounds to Treat Tuberculosis

Marina Candido Primi; Natanael Dante Segretti; Elizabeth Igne Ferreira

doi:10.2174/1574884708666131229125103

Medicinal Chemistry of New Compounds to Treat Tuberculosis

Curr Clin Pharmacol. 2015;10(2):139-159. doi: 10.2174/1574884708666131229125103.

Authors

Marina Candido Primi, Natanael Dante Segretti, Elizabeth Igne Ferreira¹

Affiliation

¹ Laboratory of Design and Synthesis of Chemotherapeutic Potentially Active against Neglected Diseases, Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo - FCF/USP Av. Prof. Lineu Prestes, 580 05508-900 Sao Paulo-SP, Brazil.

PMID: 24433443
DOI: 10.2174/1574884708666131229125103

Abstract

Tuberculosis (TB), a 19th century disease, is still present in the beginning of the Third Millennium. It has been considered pandemic, since around two billion people are infected with M. tuberculosis. Multi-drug resistant TB has been the biggest challenge for chemotherapy. In order to face this severe health problem, many institutions, private and public ones, have been investing in the search for new and better drug candidates. The pipeline of potential anti-TB drugs presents new molecules and formulations that have been submitted to pre-clinical and clinical assays. Medicinal Chemistry has an important role towards the objective of finding new leads through classic and modern processes. This paper reviews some aspects of this search, emphasizing the features of the main compounds under investigation and those that are in preliminary and final clinical trials and includes the contribution of our laboratory (LAPEN) in the area of designing new anti-TB drug candidates.

Keywords: Anti-TB pipelines; LAPEN contribution; designing anti-TB drug candidates; natural products; new anti-TB candidates; new anti-TB leads; tuberculosis.